<DOC>
	<DOCNO>NCT01814917</DOCNO>
	<brief_summary>The Primary Objectives study assess long-term efficacy treatment colestilan ( MCI-196 ) ( include combination therapy ) ass long-term safety treatment colestilan ( MCI-196 ) ( include combination therapy ) .</brief_summary>
	<brief_title>Long-term Extension Study MCI-196</brief_title>
	<detailed_description>This study terminate insufficient patient recruitment . There safety concern .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>The subject and/or parent ( ) /guardian ( ) must capable provide informed consent , assent applicable , agreement regional requirement . The subject complete either shortterm study , MCI196E14 MCI196E16 The subject withdrawn MCI196E14 , eligible enter study accord follow rule , define MCI196E14 : Hyperphosphataemia : Subjects experience hyperphosphataemia , define increase serum phosphorus [ P ] level agerelated upper limit normal ( ULN ) two consecutive occasion , withdrawn Investigator order proceed study , flexible dosing colestilan ( MCI196 ) available . Subjects withdraw MCI196E14 due hyperphosphataemia may enter study Week 6 shortterm study , follow two consecutive outofrange P value ( one obtain Week 3 one obtain Week 6 ) . After Week 6 , subject meet criterion may enter study time ( two consecutive outofrange P value obtain time Week 6 schedule unscheduled visit ) . Hypercalcaemia : Subjects treat CBPB experience hypercalcaemia may withdraw shortterm study discretion Investigator order proceed study time , flexible dosing colestilan ( MCI196 ) available . The subject current clinically significant medical comorbidities , may substantially compromise subject safety , expose undue risk , interfere significantly study procedure , opinion Investigator , make subject unsuitable inclusion study ( e.g. , subject currently history seizure disorder , dysphagia , swallow disorder , predisposition current bowel obstruction , ileus severe gastrointestinal [ GI ] disorder chronic severe constipation [ judge Investigator ] , intestinal stenosis , intestinal diverticulum , sigmoid colitis , GI ulcer , current history GI bleeding , major GI tract surgery ) . The subject expect receive immunosuppressant treatment course study . The subject consider unstable his/her current treatment CKD within one month prior enrolment ( e.g. , subject start treatment vitamin D analogue , agents/procedures may influence bone mineral metabolism [ i.e. , serum P calcium ( Ca ) level ] ) . The subject consider noncompliant study procedure opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>